LLY

1,009.7

-2.27%↓

JNJ

242.53

-0.95%↓

ABBV

223.88

-1.59%↓

NVS

165.21

-1.51%↓

MRK

119.49

-2.57%↓

LLY

1,009.7

-2.27%↓

JNJ

242.53

-0.95%↓

ABBV

223.88

-1.59%↓

NVS

165.21

-1.51%↓

MRK

119.49

-2.57%↓

LLY

1,009.7

-2.27%↓

JNJ

242.53

-0.95%↓

ABBV

223.88

-1.59%↓

NVS

165.21

-1.51%↓

MRK

119.49

-2.57%↓

LLY

1,009.7

-2.27%↓

JNJ

242.53

-0.95%↓

ABBV

223.88

-1.59%↓

NVS

165.21

-1.51%↓

MRK

119.49

-2.57%↓

LLY

1,009.7

-2.27%↓

JNJ

242.53

-0.95%↓

ABBV

223.88

-1.59%↓

NVS

165.21

-1.51%↓

MRK

119.49

-2.57%↓

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Atvērts

2.8 -9.39

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.73

Max

3.21

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-6.5M 11M
Iepriekšējā atvēršanas cena	12.19
Iepriekšējā slēgšanas cena	2.8

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. febr. 23:25 UTC

Karstas akcijas

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026. g. 25. febr. 23:15 UTC

Peļņas

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026. g. 25. febr. 23:54 UTC

Tirgus saruna

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026. g. 25. febr. 23:47 UTC

Peļņas

Ferrovial 4Q Net EUR197M >FER.MC

2026. g. 25. febr. 23:45 UTC

Peļņas

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026. g. 25. febr. 23:42 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026. g. 25. febr. 23:38 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Company's Business Operations Remain Normal >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY EPS CNY47.67 >TCOM

2026. g. 25. febr. 23:06 UTC

Peļņas

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026. g. 25. febr. 23:01 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026. g. 25. febr. 23:00 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 25. febr. 23:00 UTC

Tirgus saruna

Peļņas

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026. g. 25. febr. 22:56 UTC

Tirgus saruna

Peļņas

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026. g. 25. febr. 22:43 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026. g. 25. febr. 22:40 UTC

Tirgus saruna

Peļņas

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026. g. 25. febr. 22:40 UTC

Peļņas

Karoon Energy Says Search for New CFO Well Advanced

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says CFO Ray Church to Leave Company

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026. g. 25. febr. 22:38 UTC

Peļņas

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.